Trial Profile
A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Keratoconjunctivitis sicca
- Focus Therapeutic Use
- Sponsors Acucela; Kubota Vision
- 20 Feb 2020 According to an Acucela media release, the company has changed its name to Kubota Vision, effective from 1 Apr 2020.
- 19 Apr 2014 New trial record